This inventor holds 2 USPTO granted patents. Top assignee: Ludwig Institute for Cancer Research Limited. Active years: 2000-2003.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2000-2003
Title: Jean Edouard Gairin: Innovator in Cancer Research
Introduction
Jean Edouard Gairin is a notable inventor based in Toulouse, France. He has made significant contributions to the field of cancer research, particularly in the development of modified peptides that can enhance the immune response against melanoma.
Latest Patents
Gairin holds 2 patents related to structurally modified peptides that are resistant to peptidase degradation. His latest patents focus on the identification of peptide analogues of the MZ2-E antigen, which are recognized by autologous CD8 cytotoxic T-lymphocytes. These inventions involve the reception of specific peptide analogues by HLA molecules, forming a complex that can be recognized by cytolytic T cells, leading to the lysis of the complex. This identification can be utilized in both diagnostics and therapeutic applications.
Career Highlights
Gairin is affiliated with the Ludwig Institute for Cancer Research Limited, where he continues to advance his research in cancer immunology. His work has the potential to significantly impact the treatment of melanoma and other cancers.
Collaborations
He has collaborated with notable colleagues such as Maha Ayyoub and Benoit Van Den Eynde, contributing to a collaborative environment that fosters innovation in cancer research.
Conclusion
Jean Edouard Gairin's work exemplifies the intersection of innovation and medical research, particularly in the fight against cancer. His contributions through patented inventions are paving the way for new therapeutic strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile